Physician Quick Search
By Name:
By Specialty:
314-TOP-DOCS
When you need to get the name of one of the nation’s top doctors as close to home as St. Louis, just call 314-TOP-DOCS (314-867-3627) or toll free 1-866-867-3627. This is the physician referral and health information line from Barnes-Jewish Hospital.
Your Healthy Update

Like us on Facebook
Text Size: S M L
Search

Internal Medicine / Hematology

Morey A. Blinder, MD

Current Position
Professor, Medicine
Division of Hematology
Associate Professor, Pathology and Immunology


Specialty Areas
Hematology
Oncology

Patients Seen At
Center for Advanced Medicine
Siteman Cancer Center
4921 Parkview Place, B, 7
St. Louis, MO  63110
314-362-7216
Fax:   314-362-1608
View Floor Map  View Campus Map   View Driving Directions

Mailing Address
Washingon University School of Medicine, Division of Hematology
660 South Euclid Avenue, Campus Box 8125
St. Louis, MO  63110

Areas of Clinical Interest
Bleeding disorders, chronic leukemia, myeloma, anemia, iron deficiency anemia, red blood cell disorders, sickle cell disease, venous thromboembolism, transfusion therapy, Von Willebrand's disease, hemophilia, anticoagulation and blood thinners

Board Certification
Hematology -- Certified
Medical Oncology -- Certified
Internal Medicine -- Certified

Medical Education
B.S.: University of Notre Dame, Notre Dame, Indiana, 1977
Medical School: St. Louis University School of Medicine, St. Louis, Missouri, 1981
Residency: Internal Medicine, University of Illinois School of Medicine, Chicago, Illinois, 1984
Fellowship: Hematology, University of Washington School of Medicine, Seattle, Washington, 1986
Fellowship: Post-doctoral research Hematology-Oncology, Washington University School of Medicine, St. Louis, MO, 1990
Hospital Affiliations
Barnes-Jewish Hospital

Honors and Awards
Listed in Best Doctors in America, 2002-2013 (Best Doctors, Inc.)
Listed in America's Top Doctors, 2002-2010 (Castle Connolly Medical Ltd.)
Neville Grant Award for Clinical Excellence, 1999

Patents
U.S. Patent Number 5,102,995; "DNA Encoding Modified Heparin Cofactor II;" Inventors: Douglas M. Tollefsen, Vivianna M. Derechin, Morey A. Blinder
1992

U.S. Patent Number 5,118,793; "Modified Heparin Cofactor II;" Inventors: DM Tollefsen, VM Derechin, and MA Blinder

Disclosure of Financial Interests with Industry
Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Dr. Morey A. Blinder reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
Company
Royalties
Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product.
Consulting &
Advisory Boards
Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board.
Speaker Fees
Speaker Fees: Companies may pay faculty to speak to professional audiences about their products.
Amgen  $1,000-$10,000 $10,001-$25,000 
Glaxo Smith Kline   $10,001-$25,000 
To learn more about Washington University's policies on collaborations with industry, click here.

Selected or Recent Journal Articles
Blinder MA, Geng B, Lisker-Melman M, Crippin JS, Korenblat K, Chapman W, Shenoy S, Field JJ. Successful orthotopic liver transplantation in an adult patient with sickle cell disease and review of the literature. Hematol Rep. 2013 May 2;5(1):1-4.

Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer. 2013 May;60(5):828-35.

Knight-Perry JE, de Las Fuentes L, Waggoner AD, Hoffmann RG, Blinder MA, Dávila-Román VG, Field JJ. Abnormalities in cardiac structure and function in adults with sickle cell disease are not associated with pulmonary hypertension. J Am Soc Echocardiogr. 2011 Nov;24(11):1285-90.

Cohen RT, Madadi A, Blinder MA, DeBaun MR, Strunk RC, Field JJ. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol. 2011 Sep;86(9):756-61.

Cohen RT, DeBaun MR, Blinder MA, Strunk RC, Field JJ. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood. 2010 May 6;115(18):3852-4.

Blinder MA. Commentary. Clin Chem. 2010 Jan;56(1):19-20.

Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol. 2009 Jul;84(7):418-21.

Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MR. Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease. Am J Hematol. 2009 Apr;84(4):231-3.

Field JJ, Krings J, White NL, Yan Y, Blinder MA, Strunk RC, Debaun MR. Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease. Am J Hematol. 2009 Mar;84(3):158-60.

Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol. 2008 Apr;83(4):307-10.

Krem MM, Pan L, Blinder MA. (18)F-FDG-PET-facilitated diagnosis of lymphoma presenting with fever of unknown origin and cold agglutination. Leuk Lymphoma. 2007 Mar;48(3):619-22. No abstract available.

Lau MW, Blinder MA, Williams K, Galatz LM. Shoulder arthroplasty in sickle cell patients with humeral head avascular necrosis. J Shoulder Elbow Surg. 2007 Mar-Apr;16(2):129-34. Epub 2007 Jan 31.

Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007 Jan;13(1):46-50.

Field JJ, Giannone L, Bessler M, Blinder MA. Immunosuppressive therapy for acute porphyria: safety and efficacy in a patient with bone marrow failure. Pharmacotherapy. 2006 Nov;26(11):1662-6.

Kravtsov DV, Wu W, Meijers JC, Sun MF, Blinder MA, Dang TP, Wang H, Gailani D. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood. 2004 Jul 1;104(1):128-34. Epub 2004 Mar 16.

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Morey A. Blinder

Washington University Physicians are the medical staff of  Barnes-Jewish Hospital and Children's Hospital - St. Louis Employment   About Us   Top Stories   For Your Protection      Site Map
Copyright 2014 Washington University School of Medicine
Copyright 2014 Washington University School of Medicine